Jim Pantelas’ Post

I'm so excited to be part of this conversation at AACR's Annual Meeting! And, I'm honored to be on this panel! Maintaining equipoise in an era of social media, patient awareness, and global sharing of trial results is more than just becomming an issue - it is an issue.

I'm so excited to be part of this conversation at AACR's Annual Meeting! And, I'm honored to be on this panel! Maintaining equipoise in an era of social media, patient awareness, and global sharing of trial results is more than just becomming an issue - it is an issue.

This could be really consequential. Dr. Steven Dubinett has been named Dean of UCLA School of Medicine. This is a lung cancer specialist - a pulmonologist that was previously director of UCLA's Lung Cancer Ressearch Program - and he's now dean over a school with almost $2B in annual research funding. This may not mean a lot outside my lung cancer community - but it has potential to make a huge impact within it. And it will change how LC docs are looked at everywhere. As Jamie L. Studts says, lung cancer researchers are turning into the cool kids, and this goes a long way to proving him right! https://lnkd.in/gfSsR5vb

I'll be there. Will you?

These two videos were from the National Lung Cancer Round Table Annual Meeting held in December 2022 in Washington DC. The round table and the meeting were hosted by American Cancer Society, and I don’t know what ACS wants to do with them, or how they’ll use them, but I have been told that I can share them. Drew Moghanaki is a Radiation Oncology doc at UCLA and the VA, and is running a couple of large, national research efforts at VA. In my lung cancer world he's kind of a big deal. He's also someone I consider to be a friend. When we sat down in front of the cameras we had no idea what we would be talking about, and we had no script or agenda, so these were just us winging it - with some awesome editing by Keith Singer! This was just fun! https://lnkd.in/gq36S5hd https://lnkd.in/g8z6S9_u Video credit: Keith Singer, @catchitintime

Our ask for Congress is to raise the funding for the Lung Cancer Research Program to $60 million in FY-23. This would fund the program to award more research than ever before, and to continue our movement toward finding more treatments for this disease that still kills over 130,000 Americans a year. And, while that's down from over 150,000 a year not so long ago, it's still far too many. This link will take you to a place to send your note to your Representative and Senators. Please take the minute it takes to support this effort by signing on. We're finally moving the needle on fighting this disease - Can you help us by making sure we have enough gas in the tank to finish the race? https://lnkd.in/d9Dg958r

We are excited to invite you and your colleagues to the American Cancer Society National Lung Cancer Roundtable’s 5th Annual Meeting! Details for this virtual event are below: Theme: Disparities to Equity: Moving the Needle on Lung Cancer Date: Monday, December 6th and Tuesday, December 7th  Time: 10:00am-4:00pm ET/7:00am-1:00pm PT each day Registration is now open!   The meeting will feature the work of those who are shaping a more equitable direction to lung cancer care and control in areas such as risk reduction, early detection, tobacco prevention and treatment, diagnosis and therapy, survivorship, and policy. The overarching goal of the meeting is to address the determinants of minority health and cancer-related health disparities to advance health equity across the lung cancer continuum.   This virtual meeting will be highlighted by keynote presentations and conversations led by Monica Webb Hooper, PhD, Deputy Director of the National Institute on Minority Health and Health Disparities, and Robert A. Winn, MD, Director of the Massey Cancer Center at Virginia Commonwealth University. In addition, the NLCRT will showcase its strategic priority committees’ work and its initiatives that focus on eliminating lung cancer stigma, promoting lung cancer screening implementation, uptake, and adherence, and optimizing lung cancer biomarkers in practice. Through the NLCRT, we are working to ensure that no one is disadvantaged in their fight against lung cancer because of their socioeconomic status, their race or ethnicity, their sexual orientation, their gender identity, their disability status, their insurance status, or where they live.   Since we will be hosting the meeting once again virtually, we are pleased at the opportunity to offer attendance at no cost and all are welcome, including clinicians, researchers, public health experts, advocates, and individuals at risk for lung cancer or those diagnosed with lung cancer, and their families. https://lnkd.in/gxJFezyp